1054 citations
,
February 1998 in “The New England Journal of Medicine” In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.
April 2004 in “Journal watch” Finasteride effectively reduces the need for surgery and urinary issues in men with BPH over the long term.
March 2015 in “The Journal of Urology” This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.
March 2009 in “The Journal of Urology” This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.
24 citations
,
January 1996 in “The Prostate” This study demonstrated that 12 months of 5 mg daily finasteride treatment reduced prostate volume, dihydrotestosterone, and prostate-specific antigen levels, while improving urinary flow rates and symptom scores in benign prostatic hyperplasia patients.